COVID-19 vaccine Corbevax receives Drug Controller General of India’s approval for Emergency Use Authorization
Tweeted by AIR
Another indigenous COVID-19 vaccine Corbevax has received the Drug Controller General of India’s approval for Emergency Use Authorization. Corbevax is developed by Biological-E Limited, which is India’s first indigenously developed Receptor Binding Domain protein sub-unit vaccine for COVID-19.
The Department of Biotechnology and its Public Sector Undertaking, Biotechnology Industry Research Assistance Council (BIRAC), have supported Biological-E’s COVID-19 vaccine candidate from pre-clinical stage to Phase-III clinical studies. The vaccine candidate was provided financial support under COVID-19 Research Consortium through the National Biopharma Mission. Later, support was provided under Mission COVID Suraksha for clinical development. Corbevax is a 2-dose vaccine administered intramuscularly and can be stored at 2ºC to 8ºC.
The Ministry of Science and Technology has said, Phase-III clinical trials have demonstrated that Corbevax vaccine is safe, well-tolerated, and highly immunogenic.
Secretary of Department of Biotechnology Dr Rajesh Gokhale said, emergency use authorization to Corbevax is yet another example of a successful academia-industry collaboration. He said, this vaccine will sharpen the country’s efforts in ending the pandemic. He said, the development of indigenous vaccines to fight the pandemic will also inspire the country’s scientists and manufacturers to resolve the problems of the country.
Managing Director of Biological-E Limited, Mahima Datla thanked Prime Minister Narendra Modi for making vaccination a national mission. She said, Mr. Modi’s vision and the advance commitments Biological-E received towards Corbevax were instrumental in our ability to scale up and manufacture at such huge capacities.